United States Patent 6,011,020: Scope, Claim Construction, Expiration, and Aptamer Patent Landscape

U.S. Patent No. 6,011,020 covers covalent conjugates of polyethylene glycol, or PEG, with nucleic-acid ligands, principally aptamers, where the PEG conjugation improves pharmacokinetic performance. The patent also covers PEG-aptamer complexes incorporated into lipid constructs, targeted to cellular locations, or combined with therapeutic or diagnostic agents.

The patent issued on January 4, 2000, from an application filed in 1997 and claims priority to an earlier 1996 filing. Its 20-year patent term ended in 2017. The patent is therefore no longer an enforceable barrier to U.S. commercialization. Its historical importance remains material because it sits at the intersection of SELEX-derived aptamers, PEGylation, targeted delivery, and the development of pegaptanib, marketed as Macugen.

What does U.S. Patent 6,011,020 cover?

The patent has two principal independent claim categories:

Claim category	Independent claim	Protected subject matter
Composition	Claim 1	A therapeutic or diagnostic complex containing a nucleic-acid ligand covalently linked to PEG of at least approximately 1,000 Daltons
Method	Claim 14	A method of improving the pharmacokinetic properties of a nucleic-acid ligand by covalently linking it to PEG of at least approximately 1,000 Daltons

The claims are directed to aptamer-like nucleic-acid ligands rather than ordinary antisense oligonucleotides, naturally occurring receptor-binding nucleic acids, or nucleic acids whose binding depends primarily on Watson-Crick base pairing.

The central technical proposition is:

PEGylation of a target-binding nucleic-acid ligand can improve pharmacokinetics relative to the unmodified ligand.

The claim set does not require a particular nucleotide sequence, target protein, therapeutic indication, PEG chemistry, linker sequence, or dose. That breadth was commercially significant, but it also creates potential claim-construction and validity issues.

How should claim 1 be construed?

Claim 1 requires each of the following limitations:

A therapeutic or diagnostic complex.
A nucleic-acid ligand.
PEG covalently linked to the nucleic-acid ligand.
PEG having a molecular weight of at least approximately 1,000 Daltons.
Specific binding affinity between the nucleic-acid ligand and a target molecule.
A target molecule that is a three-dimensional chemical structure other than a polynucleotide.
Binding that does not predominantly depend on Watson-Crick base pairing or triple-helix binding.
A nucleic acid that is not a naturally functioning nucleic acid known to be bound by the target.
Improved pharmacokinetic properties compared with the unmodified nucleic-acid ligand.

What is the practical scope of the nucleic-acid-ligand limitation?

The claim is directed primarily to aptamers selected for binding to proteins, small molecules, cells, or other three-dimensional targets. A conventional antisense oligonucleotide that binds an RNA through Watson-Crick base pairing would ordinarily fall outside the express target and mechanism limitations.

The patent language is broader than a claim limited to a specific aptamer sequence. A competing product could therefore fall within the original claim if it used:

A DNA, RNA, or modified nucleic-acid aptamer;
A PEG conjugate of at least approximately 1,000 Daltons;
Covalent attachment between PEG and the ligand;
A three-dimensional non-polynucleotide target; and
Demonstrable pharmacokinetic improvement.

The claim does not expressly require that the ligand be generated by SELEX. That process appears in dependent claims 2, 3, and 15, but the broad independent claims do not require it.

What do claims 2 through 3 and 15 cover?

Claims 2, 3, and 15 narrow the patent to ligands identified through an iterative selection and amplification process corresponding to SELEX.

The required process includes:

Contacting a candidate nucleic-acid mixture with a target;
Partitioning higher-affinity nucleic acids from the unbound or lower-affinity population;
Amplifying the selected nucleic acids; and
Repeating the partitioning and amplification cycle in the case of claims 3 and 15.

These claims are narrower than claims 1 and 14 because they require a particular discovery method. A product made with a rationally designed aptamer, a pre-existing ligand, or a ligand obtained through a non-amplification screening method may avoid these dependent claims while still raising issues under the independent claims.

The SELEX limitations also create factual questions regarding:

The identity of the starting candidate mixture;
Whether amplification occurred;
Whether the selection cycle was repeated;
The degree of enrichment;
Whether the commercial ligand is the same ligand identified through the claimed process.

What formulations are protected by claims 4 through 6 and 16 through 18?

Claims 4 through 6 cover the addition of a lipid construct to the PEG-nucleic-acid-ligand complex. The claims progress from broad to narrow:

Claim	Limitation
4	Lipid construct
5	Lipid bilayer vesicle
6	Liposome
16	Method involving a lipid construct
17	Method involving a lipid bilayer vesicle
18	Method involving a liposome

These claims could reach a PEG-aptamer associated with a liposomal or vesicular delivery system. The claims do not appear limited to a particular lipid composition, particle size, encapsulation method, surface density, or administration route.

The claims are narrower than claim 1 because a formulation must contain the lipid construct. A PEG-aptamer administered as a soluble conjugate would not satisfy the lipid limitations, although it could still implicate the broader composition or method claims.

What targeting and intracellular-delivery limitations appear in the patent?

Claims 7 and 19 cover targeting the complex or ligand to a preselected location.

Claims 8, 9, 20, and 21 address intercellular and intracellular target molecules. Claim 10 narrows the intracellular category by requiring enhanced cellular uptake relative to the unconjugated nucleic-acid ligand.

These limitations are relevant to:

Cell-targeting aptamers;
Internalizing aptamers;
Aptamer-drug conjugates;
Aptamer-decorated nanoparticles;
Intracellular diagnostic probes;
Targeted delivery to tumor, vascular, hepatic, immune, or other cell populations.

The term "enhanced cellular uptake" introduces a comparative limitation. A product owner would need comparative data against the unmodified ligand. The claim does not specify a required percentage increase, assay, cell type, exposure period, or measurement endpoint.

What therapeutic and diagnostic payloads are covered?

Claims 11 through 13 and 22 through 24 cover an additional therapeutic or diagnostic agent.

The relevant arrangements include:

An additional agent associated with the PEG;
An agent covalently associated with the PEG;
An agent attached to the nucleic-acid ligand;
A payload covalently attached to the PEG.

The patent therefore reaches more than a PEGylated aptamer used alone. It also addresses multi-component constructs in which the aptamer provides targeting, PEG provides pharmacokinetic modification, and a separate agent provides therapeutic or diagnostic activity.

Potential payload categories include small-molecule drugs, toxins, imaging agents, radionuclides, proteins, oligonucleotides, and other diagnostic or therapeutic materials, subject to the claim language and applicable construction of "associated," "attached," and "covalently associated."

How strong was the patent estate for PEGylated aptamers?

Historically, the patent had a broad conceptual scope but several built-in limitations.

Strengths

The independent claims were not limited to one aptamer sequence.
The claims covered both compositions and methods.
The PEG threshold was relatively low at approximately 1,000 Daltons.
The claims addressed pharmacokinetic improvement, a central commercial problem for naked aptamers.
The claims covered targeted delivery and combination constructs.
The claims were positioned between foundational SELEX technology and product-specific aptamer patents.

Weaknesses

The patent required covalent PEG attachment.
The nucleic-acid ligand had to bind a three-dimensional target through a mechanism not predominantly based on Watson-Crick or triple-helix pairing.
The composition claims required improved pharmacokinetic properties relative to the unconjugated ligand.
The target could not be a polynucleotide.
Dependent claims requiring SELEX, liposomes, intracellular targeting, or payload attachment were materially narrower.
Prior-art challenges could focus on earlier PEG-nucleic-acid conjugates, aptamer disclosures, SELEX publications, and routine PEGylation practices.

The patent’s current practical strength is zero as an exclusionary right because the term has expired. Its remaining value is historical, technical, and evidentiary. It can still be relevant in freedom-to-operate analyses as prior art and as part of the prosecution history of later aptamer patents.

When did U.S. Patent 6,011,020 lose exclusivity?

The patent’s standard 20-year term ran from its earliest effective nonprovisional filing date and ended in 2017. Public patent records identify the patent as expired for failure of the statutory term to remain in force. The patent cannot now support a U.S. infringement action against a generic, biosimilar, pharmaceutical company, or research organization.[1]

Event	Date or period
Earliest priority period	1996
U.S. application filing	1997
Patent issue	January 4, 2000
Standard 20-year term expiry	2017
Current enforceability	Expired

The exact term calculation should be distinguished from the expiration dates of related family members. Continuations, divisionals, and patents claiming different priority chains may have different terms.

What is the Orange Book status of Patent 6,011,020?

Patent 6,011,020 is not an active Orange Book exclusivity barrier. The Orange Book lists patents associated with approved small-molecule and certain other drug products when submitted by the NDA holder and accepted under FDA listing standards. An expired patent does not block an ANDA applicant from receiving approval or launching a product.[2]

For pegaptanib, the commercial product was Macugen, approved by FDA in 2004 for neovascular age-related macular degeneration.[3] The commercial and patent record for Macugen involved product-specific aptamer patents, formulation and use rights, and licensing arrangements beyond the single patent analyzed here.

A patent appearing historically in an NDA file or patent dispute is not equivalent to a currently enforceable Orange Book barrier. The operative business question is whether an unexpired, properly listed patent still carries a valid use code or drug-substance, drug-product, or method-of-use claim.

Did Patent 6,011,020 create biosimilar risk?

No. Patent 6,011,020 does not create a current biosimilar barrier.

Pegaptanib is a chemically synthesized oligonucleotide aptamer, not a protein biologic. A competing pegaptanib product would generally be analyzed under the abbreviated new drug application framework for a chemically synthesized drug, subject to FDA’s treatment of the specific product and dosage form. The biosimilar pathway under section 351(k) is directed to biological products and is not the ordinary pathway for a synthetic aptamer.[4]

A successor product could nevertheless face:

Drug-substance characterization issues;
Sequence identity requirements;
PEG-conjugation comparability questions;
Sterility and injectable-product requirements;
Bioequivalence or clinical endpoint requirements;
Device and administration differences;
Remaining product-specific patents.

Which companies were associated with the technology?

The patent was associated with the early aptamer commercialization field, including NeXstar Pharmaceuticals and later Gilead Sciences. NeXstar was acquired by Gilead in 1999. Gilead subsequently licensed commercialization rights for pegaptanib to Eyetech Pharmaceuticals, with Pfizer later becoming involved in commercialization.[5]

Company	Relevance
NeXstar Pharmaceuticals	Early assignee and aptamer commercialization company
Gilead Sciences	Successor to NeXstar and holder of substantial aptamer-related rights
Eyetech Pharmaceuticals	Commercialization partner for pegaptanib
Pfizer	Commercial partner for Macugen
Ophthotech, later Iveric Bio	Later corporate lineage associated with ophthalmic development programs, but not a continuation of this expired patent right

These relationships should not be treated as evidence that every company-held aptamer patent was licensed under Patent 6,011,020. Aptamer portfolios typically included separate SELEX, sequence, target, formulation, PEGylation, and therapeutic-use patents.

What patent litigation affected pegaptanib and related aptamer technology?

The major legal risk around pegaptanib historically came from portfolio overlap rather than from the present enforceability of Patent 6,011,020. Relevant disputes could involve:

Foundational SELEX patents;
VEGF-binding aptamer sequence patents;
PEGylation and conjugation patents;
Ophthalmic formulation patents;
Method-of-treatment claims;
Licensing and ownership disputes.

Because Patent 6,011,020 expired in 2017, it cannot support a current Paragraph IV litigation campaign. Any present patent dispute concerning a pegaptanib competitor would have to rely on a different unexpired patent.

Are there current Paragraph IV challenges based on Patent 6,011,020?

No current Paragraph IV challenge can be commercially effective against this patent because the patent has expired.

Paragraph IV certifications are directed to listed patents that are asserted to be invalid, unenforceable, or not infringed. An ANDA applicant can certify that a listed patent has expired or use a different certification route where applicable. The expiration of Patent 6,011,020 removes it as a launch-blocking patent even if it appeared in historical regulatory or litigation records.[2]

For a current generic-entry assessment, the relevant review should focus on:

Any unexpired patents listed for the reference product;
Whether the claims cover the same aptamer sequence or chemical form;
Whether PEG molecular weight and linkage chemistry are claimed;
Whether the injectable formulation has separate protection;
Whether pediatric exclusivity or regulatory exclusivity remains;
Whether a settlement agreement imposes a contractual launch restriction.

How does Patent 6,011,020 compare with foundational SELEX patents?

Issue	Patent 6,011,020	Foundational SELEX patents
Primary subject	PEGylated nucleic-acid ligands	Selection and amplification of binding nucleic acids
Product focus	Conjugate and targeted complex	Discovery platform
PEG requirement	Yes, at least approximately 1,000 Daltons	Generally no
Pharmacokinetic improvement	Express requirement in independent claims	Not the central limitation
Target	Three-dimensional non-polynucleotide	Broad target categories
SELEX process	Dependent claims	Often central to claims
Current status	Expired	Major early patents also expired or near expiration

The distinction matters in licensing and freedom-to-operate work. A company could avoid Patent 6,011,020 by using an unmodified aptamer, a noncovalent PEG association, or a different delivery strategy. That same product could still have historically implicated SELEX platform patents or sequence-specific aptamer rights.

What generic launch scenarios existed for pegaptanib?

A generic pegaptanib entrant would face a technical and regulatory pathway more complex than a conventional oral small molecule.

Scenario 1: Same aptamer and same PEG architecture

This is the most direct route. The applicant would need to match or adequately characterize:

Aptamer sequence;
Chemical modifications;
PEG size distribution;
Linkage site;
Linker chemistry;
Oligonucleotide purity;
Sterility;
Injectable formulation;
Container and administration system.

Patent 6,011,020 would not block this route after 2017, but unexpired sequence or formulation patents could have been relevant.

Scenario 2: Same target, different aptamer

A different aptamer could avoid sequence-specific claims but would require independent clinical and regulatory support. Differences in affinity, internalization, tissue distribution, immunogenicity, stability, and pharmacokinetics could undermine an abbreviated pathway.

Scenario 3: Different PEG or non-PEG modification

A ligand with a polymer other than PEG, or a noncovalent delivery system, could avoid the literal PEG limitations. It would still need to establish adequate exposure, stability, safety, and efficacy.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are technical rather than those created by Patent 6,011,020.

Important manufacturing variables include:

Solid-phase oligonucleotide synthesis;
Site-specific PEG conjugation;
Removal of unconjugated aptamer and free PEG;
Control of PEG molecular-weight distribution;
Aggregate and impurity control;
Endotoxin limits;
Sterile filtration or aseptic processing;
Long-term stability of the conjugate;
Reproducibility of biological binding activity.

The patent’s broad claim language could historically have captured multiple manufacturing routes, but expiration eliminates that exclusionary effect in the United States. Proprietary know-how, trade secrets, analytical methods, and later patents may remain commercially relevant.

What is the revenue exposure associated with the patent?

The patent’s commercial exposure was linked primarily to PEGylated aptamer therapeutics, especially pegaptanib. Macugen generated substantial early revenue after its 2004 approval, but sales declined as anti-VEGF antibody and antibody-fragment therapies gained market share. FDA approval established the regulatory precedent for an aptamer therapeutic, while the product’s commercial performance did not establish a continuing revenue stream for the expired patent.[3,5]

Revenue exposure today is therefore indirect:

No current royalty stream should be attributed solely to Patent 6,011,020 absent a surviving contract;
No U.S. launch delay can be justified by this patent alone;
Portfolio value may remain in later patents, manufacturing know-how, regulatory history, or commercial agreements;
New aptamer programs should be assessed against later composition, sequence, formulation, and use patents.

Key Takeaways

Patent 6,011,020 covers PEGylated nucleic-acid ligands, especially aptamers, with improved pharmacokinetics.
Claim 1 is a broad composition claim requiring covalent PEG attachment, PEG of at least approximately 1,000 Daltons, binding to a three-dimensional non-polynucleotide target, and improved pharmacokinetics.
Claim 14 covers the corresponding PEGylation method.
Claims 2, 3, and 15 add SELEX-style selection and amplification requirements.
Claims 4 through 6 and 16 through 18 cover lipid constructs and liposomes.
Claims 11 through 13 and 22 through 24 cover additional therapeutic or diagnostic payloads.
The patent expired in 2017 and is not a current U.S. launch barrier.
It is not a current biosimilar patent because pegaptanib is a synthetic oligonucleotide aptamer rather than a conventional biologic.
Any current freedom-to-operate analysis must focus on later sequence, formulation, use, manufacturing, and product-specific patents.
Historical licensing involving NeXstar, Gilead, Eyetech, and Pfizer should be separated from the enforceability of this expired patent.

Frequently Asked Questions

Does Patent 6,011,020 cover all PEGylated oligonucleotides?

No. The claims require a nucleic-acid ligand that specifically binds a three-dimensional target other than a polynucleotide. Conventional antisense oligonucleotides and many siRNA products would not satisfy those limitations.

Does a PEG-aptamer need to be made by SELEX to fall within claim 1?

No. SELEX is required by certain dependent claims, but claim 1 does not expressly require SELEX. A non-SELEX aptamer could still be evaluated under the independent claim.

Does the patent cover noncovalent PEG association?

The independent claims require that the nucleic-acid ligand be covalently linked to PEG. A purely noncovalent association would not literally satisfy that limitation.

Is pegaptanib the only commercial product relevant to this patent?

Pegaptanib is the principal commercial product historically associated with PEGylated aptamer technology. The claim language is not limited to pegaptanib, VEGF, ophthalmology, or any particular sequence.

Can an expired patent still matter in an aptamer licensing transaction?

Yes. It can remain relevant as prior art, as evidence of historical ownership or licensing, and as part of the technical background for later patents. It cannot, by itself, impose a current U.S. patent exclusion.

References

United States Patent and Trademark Office. (2000). U.S. Patent No. 6,011,020, Nucleic acid ligands with improved pharmacokinetics. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2004). FDA approves Macugen for treatment of age-related macular degeneration. FDA.
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. FDA.
Gilead Sciences, Inc. (1999). Form 10-K and corporate transaction disclosures concerning NeXstar Pharmaceuticals. U.S. Securities and Exchange Commission.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0957929	⤷ Start Trial	91252	Luxembourg	⤷ Start Trial
European Patent Office	0957929	⤷ Start Trial	300234	Netherlands	⤷ Start Trial
European Patent Office	0957929	⤷ Start Trial	PA2006004	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,011,020

Summary for Patent: 6,011,020